ABSTRACT
The increasing use of intravenous immunoglobulin (IVIG) in the past two decades has stimulated an interest in pharmacoeconomics and evidence-based medicine with regard to this drug.
IVIG IN SPONTANEOUS ABORTION
Gooi and colleagues presented an open study on the efficacy of IVIG in the treatment of spontaneous recurrent miscarriage based on 13 years’ experience (1). The success rate in 82% of 16 women with recurrent pregnancy loss encourages the setting up of a randomized, controlled trial (RCT) of IVIG in this clinical problem. Nevertheless, despite these and other positive results, the overall outcome of IVIG in recurrent spontaneous abortion reported in various studies remains contradictory.
